The Biocodex story started modestly, bringing Saccharomyces boulardii CNCM I-745® to market in France as a therapeutic brand named ULTRA-LEVURE®.
This single celled, non-pathogenic yeast therapeutic has since become the world’s number one yeast-based probiotic in the world.
From this scientific and commercial success, Biocodex has built its worldwide company into a diverse pharmaceutical organization with an international portfolio of products.
Today, Biocodex specializes in the following therapeutic areas:
Additional licensed products through our subsidiaries.